Critical Review: Autonomix Medical (NASDAQ:AMIX) and Pacific Biosciences of California (NASDAQ:PACB)

Autonomix Medical (NASDAQ:AMIX) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Profitability

This table compares Autonomix Medical and Pacific Biosciences of California’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Autonomix Medical	N/A	-228.82%	-186.65%
Pacific Biosciences of California	-341.47%	-326.43%	-19.40%

Analyst Ratings

This is a summary of recent recommendations and price targets for Autonomix Medical and Pacific Biosciences of California, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autonomix Medical	1	1	1	0	2.00
Pacific Biosciences of California	2	2	1	0	1.80

Autonomix Medical presently has a consensus price target of $2.00, suggesting a potential upside of 442.89%. Pacific Biosciences of California has a consensus price target of $1.67, suggesting a potential upside of 6.84%. Given Autonomix Medical’s stronger consensus rating and higher possible upside, research analysts plainly believe Autonomix Medical is more favorable than Pacific Biosciences of California.

Volatility & Risk

Autonomix Medical has a beta of -2.48, indicating that its share price is 348% less volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 2.33, indicating that its share price is 133% more volatile than the S&P 500.

Insider & Institutional Ownership

10.8% of Autonomix Medical shares are held by institutional investors. 6.2% of Autonomix Medical shares are held by insiders. Comparatively, 2.4% of Pacific Biosciences of California shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Autonomix Medical and Pacific Biosciences of California”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autonomix Medical	N/A	N/A	-$11.41 million	($3.55)	-0.10
Pacific Biosciences of California	$160.01 million	3.03	-$546.38 million	($1.84)	-0.85

Autonomix Medical has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Autonomix Medical beats Pacific Biosciences of California on 8 of the 12 factors compared between the two stocks.

About Autonomix Medical

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.